- We recently hosted Raffles Medical (SGX:BSL)’s investor meetings and came back feeling positive about its longer term growth prospects in Singapore and China.
- Extension to the current transitional care facility (TCF) arrangement – subject to a review by mid-year – and the possibility of operating additional TCFs in Singapore would be positive in the near term.
- - Read this at SGinvestors.io -
RFMD remains competitively positioned in Singapore, with potential for growth.
- In terms of pricing, Raffles Medical is more competitively placed compared to other private healthcare players in Singapore. Its group practise model, although increasing operating costs due to increased pressure on staff retention, also enables it to provide team-based patient-centred care that puts the interests of its patients as the prime focus. This, we believe, will enable it to collaborate better with the Singapore Ministry of Health on the proposed expansion of TCFs, which are supposed to augment Singapore’s public healthcare infrastructure.
- - Read this at SGinvestors.io -
China to see revenue growth.
- Read more at SGinvestors.io.
